Liposome-based nanomedicine for immune checkpoint blocking therapy and combinatory cancer therapy

Haoyuan Zhou,Cui-Yun Yu,Hua Wei
DOI: https://doi.org/10.1016/j.ijpharm.2024.123818
IF: 6.51
2024-01-23
International Journal of Pharmaceutics
Abstract:The discovery of immune checkpoint (IC) has led to a wave of leap forward in cancer immunotherapy that represents probably the most promising strategy for cancer therapy. However, the clinical use of immune checkpoint block (ICB) therapy is limited by response rates and side effects. A strategy that addresses the limitations of ICB therapies through combination therapies, using nanocarriers as mediators, has been mentioned in numerous research papers. Liposomes have been probably one of the most extensively used nanocarriers for clinical applications, with broad drug delivery and high safety. A timely review on this hot subject of research, i.e. , the application of liposomes for ICB is thus highly desirable for both fundamental and clinical translatable studies, but remains, to our knowledge, unexplored so far. For this purpose, this review is composed to address the dilemma of ICB therapy and the reasons for this dilemma. We later describe how other cancer treatments have broken this dilemma. Finally, we focus on the role of liposomes in various combinatory cancer therapy. This review is believed to serve as a guidance for the rational design and development of liposome for immunotherapy with enhanced therapeutic efficiency.
pharmacology & pharmacy
What problem does this paper attempt to address?